ARS Pharmaceuticals Inc
NASDAQ:SPRY

Watchlist Manager
ARS Pharmaceuticals Inc Logo
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Watchlist
Price: 11.18 USD -1.24%
Market Cap: 1.1B USD
Have any thoughts about
ARS Pharmaceuticals Inc?
Write Note

P/FCFE
Price to FCFE

-23.6
Current
-13.2
Median
23.4
Industry
Lower than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-23.6
=
Market Cap
1.1B USD
/
FCFE
-46m USD
All Countries
Close
 
US
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Average P/FCFE: 29.6
Negative Multiple: -23.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 222 687.7
US
Abbvie Inc
NYSE:ABBV
12.4
US
Amgen Inc
NASDAQ:AMGN
23.9
US
Gilead Sciences Inc
NASDAQ:GILD
11.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -77.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -425.8
AU
CSL Ltd
ASX:CSL
76.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
23.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5
NL
argenx SE
XBRU:ARGX
Negative Multiple: -113.6

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A

See Also

Discover More